Every patient’s cancer is unique in terms of its genetic makeup and how it responds to various forms of treatment. Dr. Rosalyn Juergens and her research team are evaluating new genetic-testing procedures that provide insight into the genes that form various types of cancer.
“My team was fortunate to receive seed funding from the Foundation for this research initiative,” says Dr. Juergens. “This funding was made possible by the generosity of donors and is helping us revolutionize how we test tumours.”
In the past, tissue samples were sent to the lab for a single genetic test. With “next-generation sequencing” of cancer genes, a number of different tests are conducted with a single tissue sample, increasing efficiency and shortening the turnaround time for receiving test results.
“We continue to take cancer research and treatment to the next level.”
Clinicians are then able to initiate the appropriate therapy sooner. This can have a significant impact on patient outcomes.
“As we continue to gain a greater understanding of how different cancers work at a genetic level, we continue to take cancer research and treatment to the next level.”